This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Quality of Care  • Patient Safety/ Medical Error  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Tale of 2 Lipid-Altering Drugs

Bruce M. Psaty, MD, PhD; Thomas Lumley, PhD

JAMA. 2008;299(12):1474-1476.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Risk factors such as high blood pressure, elevated low-density lipoprotein (LDL) cholesterol levels, and high blood glucose levels are strongly, consistently, and directly associated with the risk of major cardiovascular events, including myocardial infarction, stroke, and heart failure. Over the last several decades, the development and widespread use of drugs to reduce the level of these risk factors have been a mainstay of cardiovascular disease prevention efforts.

For new drugs designed to treat these conditions, the US Food and Drug Administration (FDA) generally uses their treatment effects on the level of the risk factor to evaluate them for approval. Risk-factor levels serve as surrogate end points for the outcomes of primary interest—the incidence of cardiovascular disease. According to the FDA guidance on lipid-lowering therapy, "The objective of lipid-altering therapy is not merely to alter serum lipids but to diminish the morbidity and . . . [Full Text of this Article]

Ezetimibe

Author Affilliations: Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, Health Services (Dr Psaty) and Biostatistics (Dr Lumley), University of Washington; and Center for Health Studies, Group Health (Dr Psaty), Seattle, Washington.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Implications of recent clinical trials on pay-for-performance
Gellad et al.
Am J Health Syst Pharm 2009;66:864-867.
FULL TEXT  

The Challenge of Designing a Treatment Trial for Warfarin-Associated Intracerebral Hemorrhage
Flaherty et al.
Stroke 2009;40:1738-1742.
ABSTRACT | FULL TEXT  

Prostate-Specific Antigen: A Misused and Maligned Prostate Cancer Biomarker
Thompson et al.
JNCI J Natl Cancer Inst 2008;100:1487-1488.
FULL TEXT  

The ENHANCE Study and Marketing Ezetimibe--Reply
Greenland and Lloyd-Jones
JAMA 2008;299:2747-2748.
FULL TEXT